Hepatocellular carcinoma screening is associated with survival benefit in silico but needs confirmation in an in vivo analysis
Hepatology
.
2018 Jul;68(1):7-9.
doi: 10.1002/hep.29776.
Epub 2018 May 10.
Authors
Ruben Hernaez
1
2
3
,
Fasiha Kanwal
1
2
3
,
Hashem B El-Serag
1
2
3
Affiliations
1
Section of Gastroenterology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX.
2
Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX.
3
Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX.
PMID:
29315712
DOI:
10.1002/hep.29776
No abstract available
Publication types
Editorial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Comment
MeSH terms
Carcinoma, Hepatocellular*
Computer Simulation
Humans
Liver Cirrhosis
Liver Neoplasms*
Mass Screening
Grants and funding
P30 DK056338/DK/NIDDK NIH HHS/United States